Little is known about the benefits and risks of the long-term use of cardiovascular drugs. Evidence from randomized clinical trials (RCTs) rarely goes beyond a few years of follow-up, but patients are often given continuous treatment with multiple drugs well into old age. We focus on 4 commonly used cardiovascular drug classes: aspirin, statins, betablockers, and angiotensin-converting enzyme inhibitors given to patients after myocardial infarction. However, the issues raised apply more broadly to all long-term medications across cardiovascular diseases and the whole of medicine. The evidence and limitations of RCTs are addressed, as well as current practice in pre-licensing trials, the increasing problems of polypharmacy (especially in the elderly), the lack of trial evidence for withdrawal of drugs, the role of regulatory authorities and other stakeholders in this challenging situation, and the potential educational solutions for the medical profession. We conclude with a set of recommendations on how to improve the situation of long-term drug use. Our attention was drawn to this issue by the personal experience of 1 of the investigators (6). He developed an episode of severe hypotension during exercise, and developed another of sinoatrial block, which led to syncope after being on a beta-blocker for >15 years, cough from an ACE inhibitor after being on ramipril for 10 years, and aspirin-induced gastrointestinal bleeding after being on the drug for 20 years.
Our attention was drawn to this issue by the personal experience of 1 of the investigators (6) . He developed an episode of severe hypotension during exercise, and developed another of sinoatrial block, which led to syncope after being on a beta-blocker for >15 years, cough from an ACE inhibitor after being on ramipril for 10 years, and aspirin-induced gastrointestinal bleeding after being on the drug for 20 years.
We suspect such risks are not uncommon. The 2 episodes due to the beta-blocker could have been fatal if immediate help had not been available, and the death would not have been attributed to the drug. Therefore, we feel it is important to challenge the assumption that the efficacy and safety of drugs given in the relatively short term remain the same over the long term and into old age. Heart Association (AHA) guidelines recommend that high-dose statin therapy should be initiated or continued in all patients with STEMI with no contraindication to its use. It is implied that continuation is long-term. Statins are also widely used for primary prevention, and although they seem to be cost-effective therapy, concerns have arisen regarding an increase in geriatric-specific adverse effects (13) and the potential of the increased incidence of diabetes (14) .
Beta-blockers prevent the action of endogenous catecholamines, and consequently, lower heart rate and blood pressure. Beta-blocker treatment after MI is associated with reduced mortality and morbidity ACE inhibitors act by blocking the reninangiotensin system, and have been shown to reduce fatal and nonfatal cardiovascular events in patients with STEMI (16) . However, although the clinical benefit is well established in high-risk subgroups, such as patients with anterior MI, ejection fractions of <40%, heart failure, previous MI, or tachycardia (7), the role of routine long-term ACE inhibitor therapy in low-risk patients after STEMI is less certain (4, 17, 18) . Current ACC/AHA guidelines declare that ACE inhibitors are reasonable for all STEMI patients, with no contraindications to their use.
Once initiated, there is no clear evidence for how long these 4 drugs should be prescribed. Additional concerns have arisen with the introduction of the fixed-dose polypill as potential life-long therapy in post-MI patients (19, 20) . Although we concentrate on post-MI patients, including those with STEMI and non-STEMI, these problems and the uncertainties regarding long-term drug use may also apply to other cardiac diseases (e.g., heart failure, atrial fibrillation) and in the primary prevention setting.
THE KNOWLEDGE GAP IN LONG-TERM USE OF CARDIOVASCULAR DRUGS
Clinicians or those writing guidelines have given little consideration to the use of drugs over decades, and trialists have used "long-term" to mean "not very short-term." Thus, in a recent publication of a In the RCT, the percentages of patients taking medications 1 to 3 years after a MI were as follows: aspirin, 100%; statin, 93%; beta-blocker, 82%; and ACE inhibitor or angiotensin receptor blocker (ARB), 80%.
In the registry, the percentages of patients on medications at 1-year of follow-up were: aspirin, 82%; statin, 73%; beta-blocker, 80%; and ACE inhibitor or ARB, 75%. However, our use of long-term relates to much longer periods; real-world, post-MI patients may well stay on such drugs for decades, although there is no direct evidence that this is beneficial. A second gap between evidence and real-world practice is that the recommended long-term use of these drugs is based implicitly on a constant relative hazard assumption, meaning that the benefits continue (and stay constant) over the long-term, when no data exist to confirm or refute this presumption. It is important to consider how the absolute risk changes over time. Many trials started follow-up in the post-acute phase of acute coronary syndrome (ACS), when the risk is high, and therefore, the benefit may be greatest. Survivors several years after an MI may be a relatively low-risk cohort, so absolute benefits may be relatively small. In the truly long term, the risks of major cardiac events and death increases with age, but whether these medications benefit elderly patients long after the initial MI remains without assurance by RCTs.
In a pre-reperfusion era meta-analysis (16) , ACE inhibitors started in the acute phase of MI showed an early absolute benefit of 5 lives saved per 1,000 patients treated in the first month. Even more importantly, this meta-analysis showed that most of this benefit was markedly reduced over the subsequent 3 years. a systematic exclusion and under-recruitment of elderly patients in cardiovascular RCTs (56) . This issue will be covered in the section on Deprescribing.
Also, the net benefit of some medications may be neutralized with the appearance of age-related adverse effects and comorbidities (drug-disease and drug-drug interactions), which are not well studied in
RCTs. This issue is discussed in the section on LongTerm Use of Medications and Aging.
In principle, we need RCTs of post-MI medications to be extended into truly long-term follow-up.
However, in practice, to achieve trials with >5 years follow-up is a major challenge, not just because of increased noncompliance and loss to follow-up, but also due to the increased costs of organizing and monitoring long-term follow-up. Thus, to fill the evidence gaps on long-term effectiveness and safety issues regarding cardiovascular drug use, and despite This table is based on the most comprehensive published meta-analyses (1-5), and includes randomized clinical trials (RCTs) with >1,000 patients and >1-year follow-up. Table 1 .
the inherent problems with potential selection bias, there is also a need for quality, large-scale registries.
PROBLEMS WITH CURRENT PRACTICE IN PRE-LICENSING TRIALS
The RCTs that the pharmaceutical industry un- RCTs of ivabradine in both stable CHD and heart failure patients (58-60) were all placebo-controlled studies, thus adding ivabradine on top of a betablocker in many patients. Thus, the opportunity for a head-to-head ivabradine versus beta-blocker comparison was missed, which is disadvantageous because 1 prime feature of both drugs is a reduction in heart rate.
We cannot expect the industry to promote these head-to-head trials in such a regulatory environment, because they understandably want the most straightforward trial progress to achieve drug licensing. 
PROBLEMS OF POLYPHARMACY
The decision to prescribe a drug is often on the basis of a single disease-oriented approach and its associated guideline recommendations for that specific drug. In a Scottish primary care population (66), 21.5% of adults received at least 4 medications, and 4.6% received $10 medications. These prevalences increased with age (36.0% and 7.4%, respectively, in those ages 60 to 69 years, and 70.4% and 18.6%, respectively, in those ages 80 years or older). Cardiovascular conditions (e.g., heart failure, ischemic heart disease, and atrial fibrillation) were associated with the highest levels of prescribing, which is consistent with clinical guidelines advocating their treatment with multiple drug classes.
Polypharmacy increases health care costs and the risks of noncompliance and of adverse drug reactions, which is enhanced by both drug-drug and drugdisease interactions (67). The pharmacodynamics of cardiovascular drugs are affected by age-related changes in end-organ responsiveness (67, 71) . Therefore, alterations to both sinus node activity and atrioventricular conduction in the elderly may lead to increased sensitivity to the bradycardic effect of beta-blockers.
In addition, the elderly experience more comorbidities, and the drugs used to treat them increase the risk of drug-disease and drug-drug interactions ( Table 3) At present, deprescribing receives insufficient attention, and there is a great need for the deprescription process to be based on objective evidence rather than solely on subjective clinical judgment.
THE NEED FOR TRIALS ON WITHDRAWAL OF DRUGS
The possibility that cardiovascular drugs may have reduced efficacy over longer medication periods is an important issue that has received little attention.
Likewise, the potential long-term harm of these drugs, enhanced by an accumulating polypharmacy, There is no good evidence base for the continuation of aspirin, statins, beta-blockers, and ACE inhibitors in the long term, and further investigation is needed.
Drug discontinuation is sometimes associated with a rebound phenomenon, which might complicate how to design a drug withdrawal trial. Thus, abrupt betablocker withdrawal may be associated with an increased risk for acute MI and sudden death (8) .
Consequently, the drug should be tapered down over 
AN EXAMPLE RCT FOR WITHDRAWAL OF BETA-BLOCKERS
The first RCTs of beta-blockade in secondary prevention after MI were published in the 1960s, and all such trials took place before primary PCI became routine practice. Beta-blocker therapy after successful primary PCI has not been studied in RCTs, but a nonrandomized comparison shows that this therapy is associated with lower 6-month mortality (51) . However, there is little evidence of continued efficacy and safety for the long-term use of beta-blockers in stable CHD (although it is common practice), and this problem should be addressed by a randomized controlled drug withdrawal study. The design essentials of such an RCT are discussed in the following (Figure 1) .
First, the eligibility criteria should encompass a broad spectrum of patients with stable CHD, with special attention paid to those who have had a MI, which would form a pre-specified subanalysis.
Patients who take beta-blockers due to the presence of documented arrhythmias, chronic heart failure, and refractory angina would need to be excluded, because withdrawal would be contrary to recommended guidelines and established patient benefit.
Second, randomization to continuation or withdrawal (using a tapering of dose according to good standard practice) would take place 6 months after a coronary event in post-MI patients or revascularization in stable patients, in the spirit of identifying patients at a routine post-procedure follow-up visit.
Because of the need for tapering and screening for any side effects, assignment could not realistically be double-blinded.
Third, the composite primary endpoint could be all-cause death, MI, and hospitalization for heart failure over a 1-year follow-up, which could be powered for a noninferiority hypothesis, but also assessed for superiority. A potential further hypothesis could focus on specific subgroups (e.g., the elderly, post-MI patients) and also on longer term follow-up, if this could be maintained. Any drug withdrawal trial with a major adverse cardiac events-type primary endpoint needs to be as large as placebo-controlled trials of drug efficacy, which could be a problem. Hence, with a hazard ratio noninferiority margin of 1.3, to achieve 80% power, requires approximately 450 patients overall to reach the primary composite endpoint. Thus, the trial would need to recruit several thousand patients.
Clearly, this would need to be a large, simple, pragmatic trial with limited data collection.
Can such a drug withdrawal RCT be funded and conducted? Is there the collective will to make such a Design of a randomized clinical trial for withdrawal of beta-blockers in stable coronary heart disease patients. *Exclude patients requiring beta-blockers due to other reasons. HF ¼ heart failure; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention.
Long-Term Use of Cardiovascular Drugs trial happen? Perhaps a smaller feasibility study is needed first to establish that such a trial is delineable.
However, the essential message is that without such trials of treatment withdrawal, there will continue to be no evidence base to determine which long-term therapies are beneficial to patients, and which are neutral or even harmful. All treating physicians, both cardiologists and others (e.g., primary care) need to avoid the trap of routine repeat-prescribing over many years, regardless of whether this is in the patient's best interests.
RESPONSIBILITIES OF REGULATORS AND OTHER STAKEHOLDERS
A better awareness of potential side effects, especially in the context of older age polypharmacy, is much needed. Also, those initiating drug use (e.g., cardiology consultants) may well be different from those handling long-term care (e.g., general practitioners). A closer dialogue across specialties is needed to ensure that a patient's total drug use, including deprescribing, is handled wisely.
Lastly, patients themselves should be encouraged to participate in decisions relating to their long-term therapy.
RECOMMENDATIONS
We conclude with a set of recommendations that relate both to a future research agenda and to improvements in patient care:
1. The gap in knowledge regarding the long-term efficacy and safety of cardiovascular drugs needs wider recognition.
2. The untested assumption that short-term drug benefit over a few years post-MI extends into long-term follow-up and older age needs to be challenged.
3. The trial evidence for beta-blockers, which began before the introduction of primary PCI, is outdated, meaning their role particularly needs to be questioned. 4 . We need to encourage more RCTs to continue into long-term follow-up, and to reflect real-world practice, such as including increased numbers of older patients.
5. Regulatory placebo-controlled trials tend to lead to a growing plethora of approved drugs, so a new paradigm (e.g., more head-to-head trials) is needed.
6. The problems of polypharmacy need to be tackled.
7. Deprescribing should be considered more often, and requires more objective evidence for its practice.
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